JoVE Logo
Faculty Resource Center

Sign In

Summary

Abstract

Introduction

Protocol

Representative Results

Discussion

Acknowledgements

Materials

References

Cancer Research

Establishment of Patient-Derived Xenograft Mouse Model with Human Osteosarcoma Tissues

Published: March 22nd, 2024

DOI:

10.3791/66491

1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, 2Key Laboratory of theory and therapy of muscles and bones, Ministry of Education
* These authors contributed equally

The present protocol describes the method for establishing a patient-derived xenograft (PDX) mouse model using human osteosarcoma tissue.

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Despite the development of new treatment plans in recent years, the prognosis for osteosarcoma patients has not significantly improved. Therefore, it is crucial to establish a robust preclinical model with high fidelity. The patient-derived xenograft (PDX) model faithfully preserves the genetic, epigenetic, and heterogeneous characteristics of human malignancies for each patient. Consequently, PDX models are considered authentic in vivo models for studying various cancers in transformation studies. This article presents a comprehensive protocol for creating and maintaining a PDX mouse model that accurately mirrors the morphological features of human osteosarcoma. This involves the immediate transplantation of freshly resected human osteosarcoma tissue into immunocompromised mice, followed by successive passaging. The described model serves as a platform for studying the growth, drug resistance, relapse, and metastasis of osteosarcoma. Additionally, it aids in screening the target therapeutics and establishing personalized treatment schemes.

Osteosarcoma is a primary bone malignancy derived from interosseous lobe cells and is most common in adolescents as well as children. It often occurs in the epiphysis of the long diaphysis and is characterized by high malignancy, early metastasis, and poor prognosis1,2. Lung metastasis is the main cause of death in osteosarcoma patients. The 5-year survival rate of patients with non-metastatic osteosarcoma is 65%-70%3. However, over the last 40 years, the 5-year survival rate (only 20%) of patients with metastatic osteosarcoma has not significantly improved, and 25% of osteosarcoma pati....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

All studies involving human tissues have been approved by the Institutional Ethics Review Committee of Longhua Hospital, affiliated with Shanghai University of Traditional Chinese Medicine (Shanghai, China) (2013LC52), and written informed consent was obtained from the patients in accordance with the Helsinki Declaration. The IACUC number for this animal study is PZSHUTCM221017013. Four-week-old male BALB/c thymus-free mice were provided with specific pathogen-free (SPF) feed and sterile water, and were housed in a singl.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

This protocol describes the detailed procedure for establishing a PDX mouse model, preserving the morphological features of human osteosarcoma after immediate transplantation of freshly resected human osteosarcoma tissue and successive passages in mice. Here, a PDX mouse model was successfully established using human osteosarcoma tissue.

Figure 3A shows a representative mouse of PDX at P0, two months after the transplantation of femoral osteosarcoma tissue from a .......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

The PDX models can simulate the characteristics of human cancers and retain more similarity with the primary tumor, including genetic and genomic alterations, histology, heterogeneity, and gene expression profile16,17,18,19. Therefore, they preserve the molecular phenotypes and genotypes of cancer patients, providing innovative approaches for studying biology and evaluating potential therapeuti.......

Log in or to access full content. Learn more about your institution’s access to JoVE content here

This work is supported by grants from (1) the National Nature Science Foundation (81973877 and 82174408); (2) Shanghai Top Priority Research Center construction project (2022ZZ01009); (3) National Key R&D Program of China (2020YFE0201600); (4) Shanghai Collaborative Innovation Center of Industrial Transformation of Hospital TCM Preparation and (5) Research Projects within Budget of Shanghai University of Traditional Chinese Medicine (2021LK047).

....

Log in or to access full content. Learn more about your institution’s access to JoVE content here

NameCompanyCatalog NumberComments
10% formalin neutral solutionWuhan Saiweier Biotechnology Co., LtdG1101-500mlFix the tissues
AutoclaveJapan Hiryama CompanyHVE-50Sterilization surgical instruments
BALB/c athymic miceShanghai SLAC Laboratory Animal Co, Ltd./Animal
CaliperYantai Green Forest Tools Co., Ltd.034180AMeasure the tumor volume
Dish (60mm)Shanghai NianYue Biotechnology Co., Ltd430166, CorningSample placment during transplantation
Disinfectant cotton ballsShanghai Honglong Industrial Co., Ltd.20230627Disinfect the skin of mice
Disposable sterile glovesGuilin Hengbao Health Protection Co., Ltd.YT21131Sterile operation
Electronic scaleShanghai NianYue Biotechnology Co., Ltd1-2000Weigh the weight of the tumor
EosinShanghai Gengyun Biotechnology Co., LtdE4009-25GHematoxylin eosin stain
HematoxylinShanghai Gengyun Biotechnology Co., LtdH3136-25GHematoxylin eosin stain
IsofluraneShenzhen RWD Life Technology Co., LtdVETEASYMouse anesthesia 
Mark penZebra Trading (Shenzhen) Co., Ltd.YYST5Mark the surgical incision
Olympus Optical microscopeJapanese Olympus CompanyBH20Scan tissue slices
Ophthalmic ointmentShanghai Gengyun Biotechnology Co., LtdSOICOEYEGRLAvoid dry eyes of mice during anesthesia
Ophthalmic scissorsShanghai NianYue Biotechnology Co., LtdY00030 JZCut the skin
Ophthalmic tweezersShanghai NianYue Biotechnology Co., LtdBS-ZER-S-100 BiosharpHold osteosarcoma tissues during transplantation
ParaffinJiangsu Shitai Experimental Equipment Co., Ltd.80200-0015Buried osteosarcoma tissue
Paraffin slicing machineLyca Microsystem (Shanghai) Trading Co., Ltd.RM2235Osteosarcoma tissue section
physiological salineGuangzhou Jinsheng Biotechnology Co., Ltd.605-004057Rinse and temporary storage of osteosarcoma tissue
ScalpelsSurgical Instrument Factory of Shanghai Medical Devices (Group) Co., Ltd.J11010-10# JZSeparation of osteosarcoma tissue and making surgical incisions
Sterile hoodThermo Fisher Technology (China) Co., Ltd.ECO0.9Surgical operation table
sterile surgical drapesHenan Huayu Medical Equipment Co., Ltd.20160090Provide sterile surgery area
Straight needle holderShanghai Gengyun Biotechnology Co., LtdJ31050 JZSuture the wound
Suture lineShanghai Pudong Jinhuan Medical Products Co., LtdF3124Suture the wound
Suture needleShanghai Pudong Jinhuan Medical Products Co., LtdF3124Suture the wound
Tissue protective solutionNanjing Shenghang Biotechnology Co., LTDBC-CFM-03Maintain the activity of tissue cells
Tube (50 mL)Shanghai Baisai, Biotechnology Co., Ltd.BLD-BL2002500Install formalin fixation solution

  1. Saraf, A. J., Fenger, J. M., Roberts, R. D. Osteosarcoma: accelerating progress makes for a hopeful future. Front Oncol. 8, 4 (2018).
  2. Ligon, J. A., et al. Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes. J Immunother Cancer. 9 (5), e001772 (2021).
  3. Miwa, S., et al. Current and emerging targets in immunotherapy for osteosarcoma. J Oncol. 2019, 7035045 (2019).
  4. Eaton, B. R., et al. Osteosarcoma. Pediatr Blood Cancer. 68 (2), e28352 (2021).
  5. Ritter, J. Osteosarcoma. Ann Oncol. 21, 320-325 (2010).
  6. Lowery, C. D., et al. Broad spectrum activity of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemo potentiator across a range of preclinical pediatric tumor models. Clin Cancer Res. 25 (7), 2278-2289 (2019).
  7. Hingorani, P., et al. Trastuzumab deruxtecan, antibody-drug conjugate targeting Her2, is effective in pediatric malignancies: a report by the pediatric preclinical testing consortium. Mol Cancer Ther. 21 (8), 1318-1325 (2022).
  8. Brennecke, P., et al. CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice. Clin Exp Metastasis. 31 (3), 339-349 (2014).
  9. Pan, B., Wei, X., Xu, X. Patient-derived xenograft models in hepatopancreatobiliary cancer. Cancer Cell Int. 22 (1), 41 (2022).
  10. Tentler, J. J., et al. Patient-derived tumor xenografts as models for oncology drug development. Nat Rev Clin Oncol. 9 (6), 338-350 (2012).
  11. Yoshida, G. J. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 13 (1), 4 (2020).
  12. Stitzlein, R. N., Wojcik, J., Sebro, R. A., Balamuth, N. J., Weber, K. L. Team approach: Osteosarcoma of the distal part of the femur in adolescents. JBJS Rev. 5 (12), 5 (2017).
  13. Kai, K., et al. Formalin fixation on Her-2 and PD-l1 expression in gastric cancer: A pilot analysis using the same surgical specimens with different fixation times. World J Clin Cases. 7 (4), 419-430 (2019).
  14. Yang, T. S., et al. A practical protocol to prepare paraffin-embedded whole tick histology sections. Ticks Tick Borne Dis. 14 (4), 102162 (2023).
  15. Chang, J., et al. Matrine inhibits prostate cancer via activation of the unfolded protein response/endoplasmic reticulum stress signaling and reversal of epithelial to mesenchymal transition. Mol Med Rep. 18 (1), 945-957 (2018).
  16. de Alava, E. Ewing sarcoma, an update on molecular pathology with therapeutic implications. Surg Pathol Clin. 10 (3), 575-585 (2017).
  17. Hidalgo, M., et al. Patient-derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4 (9), 998-1013 (2014).
  18. Eoh, K. J., et al. Comparison of clinical features and outcomes in epithelial ovarian cancer according to tumorigenicity in patient-derived xenograft models. Cancer Res Treat. 50 (3), 956-963 (2018).
  19. Stewart, E. L., et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma. J Clin Oncol. 33 (22), 2472-2480 (2015).
  20. Kresse, S. H., Meza-Zepeda, L. A., Machado, I., Llombart-Bosch, A., Myklebost, O. Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations. Cancer. 118 (2), 558-570 (2012).
  21. Dobrolecki, L. E., et al. Patient-derived xenograft (PDX) models in basic and translational breast cancer research. Cancer Metastasis Rev. 35 (4), 547-573 (2016).
  22. Abdolahi, S., et al. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Transl Med. 20 (1), 206 (2022).
  23. Deng, N., et al. Deep whole-genome sequencing identifies recurrent genomic alterations in commonly used breast cancer cell lines and patient-derived xenograft models. Breast Cancer Res. 24 (1), 63 (2022).
  24. Chen, F., et al. Generation and characterization of patient-derived xenografts from patients with osteosarcoma. Tissue Cell. 79, 101911 (2022).
  25. Fortuna-Costa, A., et al. An association between successful engraftment of osteosarcoma patient-derived xenografts and clinicopathological findings. Histol Histopathol. 35 (11), 1295-1307 (2020).
  26. Beck, J., et al. Canine and murine models of osteosarcoma. Vet Pathol. 59 (3), 399-414 (2022).

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2024 MyJoVE Corporation. All rights reserved